Отдаленные онкологические риски после лечения цервикального предрака

1. Kalliala I., Athanasiou A., Veroniki A.A., Salanti G., Efthimiou O., Raftis N. et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann. Oncol. 2020; 31(2): 213-27. https://dx.doi.org/10.1016/j.annonc.2019.11.004
2. Lin Y., Long Y., He J., Yi Q. The residual rate of HPV and the recurrence rate of CIN after LEEP with negative margins: a meta-analysis. PLoS One. 2024; 19(3): e0298520. https://dx.doi.org/10.1371/journal.pone.0298520
3. Arbyn M., Redman C.W.E., Verdoodt F., Kyrgiou M., Tzafetas M., Ghaem-Maghami S. et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017; 18(12): 1665-79. https://dx.doi.org/10.1016/S1470-2045(17)30700-3
4. Kulkarni A., Covens A., Durand N., Ghorab Z., Gien L.T., Osborne R. et al. Role of HPV in the prediction of persistence / recurrence after treatment for cervical precancer. Obstet. Gynaecol. Can. 2023; 45(10): 102171. https://dx.doi.org/10.1016/j.jogc.2023.06.006
5. Cassani C., Dominoni M., Pasquali M.F., Gardella B., Spinillo A. The role of multiple high-risk human papillomavirus infection on the persistence recurrence of high-grade cervical lesions after standard treatment: a systematic review and a meta-analysis. Acta Obstet. Gynecol. Scand. 2024; 103(6): 1028-35. https://dx.doi.org/10.1111/aogs.14827
6. Fan A., Wang C., Han C., Wang Y., Xue F., Zhang L. Factors affecting residual / recurrent cervical intraepithelial neoplasia after cervical conization with negative margins. J. Med. Virol. 2018; 90(9): 1541-8. https://dx.doi.org/10.1002/jmv.25208
7. Bittencourt D.D., Zanine R.M., Sebastião A.P.M., Ribas C.M. Risk factors for persistence or recurrence of high-grade cervical squamous intraepithelial lesions. Rev. Col. Bras. Cir. 2023; 50: e20233537. https://dx.doi.org/10.1590/0100-6991e-20233537-en
8. Ikeda M., Mikami M., Yasaka M., Enomoto T., Kobayashi Y., Nagase S. et al. Association of menopause, aging and treatment procedures with positive margins after therapeutic cervical conization for CIN 3: a retrospective study of 8,856 patients by the Japan society of obstetrics and gynecology. J. Gynecol. Oncol. 2021; 32(5): e68. https://dx.doi.org/ 10.3802/jgo.2021.32.e68
9. Giannini A., Di Donato V., Sopracordevole F., Ciavattini A., Ghelardi A., Vizza E. et al. Outcomes of high-grade cervical dysplasia with positive margins and HPV persistence after cervical conization. Vaccines (Basel) 2023; 11(3): 698. https://dx.doi.org/10.3390/vaccines11030698
10. Medina Bueno G.A., Fernández-Montolí M.E., Heydari F., Ponce J., Tous S., Peñafiel J. Impact of excision type, cone volume, and dimensions on persistence/recurrence of cervical intraepithelial neoplasia 2-3. Life (Basel). 2024; 14(8): 968. https://dx.doi.org/10.3390/life14080968
11. Byun J.M., Jeong D.H., Kim Y.N., Jung E.J., Lee K.B., Sung M.S. et al. Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia. Medicine (Baltimore). 2018; 97(51): e13606. https://dx.doi.org/10.1097/MD.0000000000013606
12. Zhang Y., Ni Z., Wei T., Liu Q. Persistent HPV infection after conization of cervical intraepithelial neoplasia– a systematic review and meta-analysis. BMC Womens Health. 2023; 23(1): 216. https://dx.doi.org/10.1186/s12905-023-02360-w
13. Sand F.L., Frederiksen K., Kjaer S.K. Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins. Gynecol. Oncol. 2022; 165(3): 472-7. https://dx.doi.org/10.1016/j.ygyno.2022.03.015
14. Heydari F., de Sanjosé S., Peñafiel Muñoz J., Fernández-Montolí M.E. Long-term reassurance with negative high-risk human papillomavirus (HR-HPV) and clear margins after large loop excision of the transformation zone (LLETZ). Cancers (Basel). 2025; 17(3): 487. https://dx.doi.org/ 10.3390/cancers17030487
15. Ciavattini A., Di Giuseppe J., Marconi C., Giannella L., Delli Carpini G., Paolucci M. et al. Hysterectomy for cervical intraepithelial neoplasia: a retrospective observational multi-institutional study. Int. J. Gynaecol. Obstet. 2022; 159(3): 679-88. https://dx.doi.org/10.1002/ijgo.14233
16. Wang J., Wang C., Su T. Risk factors for residual lesions after total hysterectomy in patients with high-grade cervical intraepithelial neoplasia. BMC Womens Health. 2024; 24(1): 369. https://dx.doi.org/10.1186/s12905-024-03212-x
17. Tanaka M., Yamanoi K., Taki M., Kitamura S., Sunada M., Chigusa Y. et al. High-grade vaginal intraepithelial neoplasia after hysterectomy for high-grade cervical intraepithelial neoplasia: Is hysterectomy a “definitive” treatment compared to conization? J. Obstet. Gynaecol. Res. 2023; 49(9): 2361-9. https://dx.doi.org/10.1111/jog.15723
18. Schockaert S., Poppe W., Arbyn M., Verguts T., Verguts J. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am. J. Obstet. Gynecol. 2008; 199(2): 113.e1-5. https://dx.doi.org/10.1016/j.ajog.2008.02.026
19. Kim J.H., Kim J., Kim K., No J.H., Kim Y.B., Suh D.H. Risk factor and treatment of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia. J. Low. Genit. Tract Dis. 2022; 26(2): 147-51. https://dx.doi.org/10.1097/LGT.0000000000000664
20. Yu D., Qu P., Liu M. Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: a retrospective study of 118 patients. J. Obstet. Gynaecol. Res. 2021; 47(5): 1624-30. https://dx.doi.org/10.1111/jog.14733
21. Wei J., Wu Y. Comprehensive evaluation of vaginal intraepithelial neoplasia development after hysterectomy: insights into diagnosis and treatment strategies. Arch. Gynecol. Obstet. 2024; 310(1): 1-10. https://dx.doi.org/10.1007/s00404-024-07530-1
22. Kesic V., Carcopino X., Preti M., Vieira-Baptista P., Bevilacqua F., Bornstein J. et al. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia. Int. J. Gynecol. Cancer. 2023; 33(4): 446-61. https://dx.doi.org/10.1136/ijgc-2022-004213
23. Iacobone A.D., Radice D., Guerrieri M.E., Spolti N., Grossi B., Bottari F. et al. Which risk factors and colposcopic patterns are predictive for high-grade VAIN? A retrospective analysis. Diagnostics (Basel). 2023; 13(2): 176. https://dx.doi.org/10.3390/diagnostics13020176
24. Bruno M.T., Panella M.M., Valenti G., Di Grazia S., Sgalambro F., Farina J. et al. Vaginal intraepithelial neoplasia (VaIN) after hysterectomy is strongly associated with persistent HR-HPV infection. Cancers (Basel). 2024; 16(14): 2524. https://dx.doi.org/10.3390/cancers16142524
25. Lu M., Hong X., Liu T., Mai B., Hu G., Sun X. Clinical characteristics and risk factors to high-grade vaginal intraepithelial neoplasia: a single-institution study. BMC Womens Health. 2025; 25(1): 44. https://dx.doi.org/10.1186/s12905-025-03585-7
26. Shen L., Zhou L., Xi X., Hou S. Retrospective analysis of 274 cases suspected vaginal intraepithelial neoplasia. Sci. Rep. 2025; 15(1): 17506. https://dx.doi.org/10.1038/s41598-025-02629-0
27. Cao D., Wu D., Xu Y. Vaginal intraepithelial neoplasia in patients after total hysterectomy. Curr. Probl. Cancer. 2021; 45(3): 100687. https://dx.doi.org/10.1016/j.currproblcancer.2020.100687
28. Preti M., Boldorini R., Gallio N., Cavagnetto C., Borella F., Pisapia E. et al. Human papillomavirus genotyping in high-grade vaginal intraepithelial neoplasia: a multicentric Italian study. J. Med. Virol. 2024; 96(2): e29474. https://dx.doi.org/10.1002/jmv.29474
29. Zhang Y.Y., Xia R., Chen D., Zhang X. Analysis of related factors of cervical intraepithelial neoplasia complicated with vaginal intraepithelial neoplasia Clin. Transl. Oncol. 2022; 24(5): 902-8. https://dx.doi.org/10.1007/s12094-021-02739-x
30. Zhang S., Saito M., Yamada S., Sakamoto J., Takakura M., Takagi H. et al. The prevalence of VAIN, CIN, and related HPV genotypes in Japanese women with abnormal cytology. J. Med. Virol. 2020; 92(3): 364-71. https://dx.doi.org/10.1002/jmv.25611
31. Farrell R., Zaunders J., Poynten I.M., Anderson L., Evans L. Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia. Gynecol. Oncol. Rep. 2024; 52: 101350. https://dx.doi.org/10.1016/j.gore.2024.101350
32. Petráš M., Dvořák V., Lomozová D., Máčalík R., Neradová S., Dlouhý P. et al. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression. Sex. Transm. Infect. 2023; 99(8): 561-70. https://dx.doi.org/10.1136/sextrans-2023-055793
33. Jentschke M., Kampers J., Becker J., Sibbertsen P., Hillemanns P. Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine. 2020; 38(41): 6402-9. https://dx.doi.org/10.1016/j.vaccine.2020.07.055
34. Casajuana-Pérez A., Ramírez-Mena M., Ruipérez-Pacheco E., Gil-Prados I., García-Santos J., Bellón-Del Amo M. et al. Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL / CIN 2-3: the VENUS study. Vaccines (Basel). 2022; 10(2): 288. https://dx.doi.org/10.3390/vaccines10020288
35. Di Donato V., Caruso G., Petrillo M., Kontopantelis E., Palaia I., Perniola G. et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. Vaccines (Basel). 2021; 9(5): 410. https://dx.doi.org/10.3390/vaccines9050410
36. Reuschenbach M., Doorbar J., Del Pino M., Joura E.A., Walker C., Drury R. et al. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023; 41(42): 6194-205. https://dx.doi.org/10.1016/j.vaccine.2023.08.047
37. Dvořák V., Petráš M., Dvořák V., Lomozová D., Dlouhý P., Králová Lesná I. et al. Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: retrospective cohort study. Hum. Vaccin. Immunother. 2024; 20(1): 2343552. https://dx.doi.org/10.1080/21645515.2024.2343552
38. Ghelardi A., Marrai R., Bogani G., Sopracordevole F., Bay P., Tonetti A. et al. Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease. Vaccines (Basel). 2021; 9(2): 83. https://dx.doi.org/10.3390/vaccines9020083

Поступила 05.11.2025

Принята в печать 03.03.2026